All In Biotech

Drug Trial Radar · NCT07198464

Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

A Prospective, Multicenter Clinical Study of Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

Oct 1, 2029

Study completion Oct 1, 2029

Sponsor

Lead sponsor
Zhengzhou UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of relmacabtagene autoleucel combined with autologous hematopoietic stem cell transplantation, orelabrutinib, and sintilimab as first-line or relapsed/refractory treatment for primary central nervous system diffuse large B-cell lymphoma.

Conditions

  • Primary Central Nervous System Lymphoma (PCNSL)

Interventions

  • Relmacabtagene autoleucel and transplantationDrug

    This study enrolled patients with primary central nervous system lymphoma, from whom mononuclear cells and hematopoietic stem cells were collected. Participants receive infusions of hematopoietic stem cells and CAR-T cells, followed by maintenance therapy with orelabrutinib and sintilimab starting on day 15 post-transplantation, for a median duration of up to 6 months and 1 year, respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival(PFS)Time frame: Up to 60 months
  2. overall response rate(ORR)Time frame: Up to 3 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.